- Cirrus Dx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) to perform SARS-COVID-19 testing. CirrusDx validated and will commercialize the Allplex™ 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test de
ROCKVILLE, Md., April 16, 2020 /PRNewswire/ -- Cirrus Dx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) to perform SARS-COVID-19 testing. CirrusDx validated and will commercialize the Allplex™ 2019-nCoV Assay, a real-time Reverse Transcriptase PCR test developed by Seegene, a South Korea-based global leader in multiplex molecular diagnostics. The Seegene test can simultaneously detect three different genes (N, E and RdRP) of SARS-CoV-2, the virus responsible for COVID-19. “As an infectious disease laboratory in the Washington D.C. area, there is a responsibility to serve the community at large,” said Kyle Armantrout, Managing Director at CirrusDx. “Partnering with Seegene to bring Allplex™ 2019-nCoV Assay to high risk communities such as long-term care centers, and healthcare providers on the front lines, is mission critical for our organizations.” The Allplex™ 2019-nCoV Assay test will be performed in the CirrusDx CLIA High Complexity Laboratory with results reporting to clinicians within 24 hours of sample receipt. About Seegene About CirrusDx
SOURCE CirrusDx | ||
Company Codes: Korea:096530 |